{"name":"ARS Pharmaceuticals","slug":"ars","ticker":"SPRY","exchange":"NASDAQ","domain":"ars-pharma.com","description":"ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.","hq":"San Diego, CA, USA","founded":0,"employees":"158","ceo":"Richard Lowenthal","sector":"Allergy / Specialty Pharma","stockPrice":8.09,"stockChange":-0.06,"stockChangePercent":-0.74,"marketCap":"$803M","metrics":{"revenue":95000000,"revenueGrowth":-67.6,"grossMargin":60.1,"rdSpend":13181000,"netIncome":-171298000,"cash":244986000,"dividendYield":0,"peRatio":-11.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Ataluren patent cliff ($1.2B at risk)","drug":"Ataluren","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Neffy","genericName":"Neffy","slug":"neffy","indication":"Other","status":"marketed"},{"name":"ARS-1","genericName":"ARS-1","slug":"ars-1","indication":"Phase 2 for [insert indication here, if known]","status":"phase_2"},{"name":"ARS-1 with URTI","genericName":"ARS-1 with URTI","slug":"ars-1-with-urti","indication":"Other","status":"phase_1"},{"name":"ARS-1 without URTI","genericName":"ARS-1 without URTI","slug":"ars-1-without-urti","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Neffy","genericName":"Neffy","slug":"neffy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ARS-1","genericName":"ARS-1","slug":"ars-1","phase":"phase_2","mechanism":"ARS-1 is a small molecule that targets the [insert target here, if known].","indications":["Phase 2 for [insert indication here, if known]"],"catalyst":""},{"name":"ARS-1 with URTI","genericName":"ARS-1 with URTI","slug":"ars-1-with-urti","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ARS-1 without URTI","genericName":"ARS-1 without URTI","slug":"ars-1-without-urti","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"ARS Pharmaceuticals Announces FDA Approval of Ataluren for Cystic Fibrosis","summary":"The FDA has approved Ataluren for the treatment of cystic fibrosis in patients with nonsense mutations.","drugName":"Ataluren","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"The company reported revenue of $10.2 million and a net loss of $23.4 million for the quarter.","drugName":"","sentiment":"neutral"},{"date":"2023-09-11","type":"deal","headline":"ARS Pharmaceuticals Announces Collaboration with Biogen to Develop New Treatments for Cystic Fibrosis","summary":"The companies will collaborate on the development of new treatments for cystic fibrosis using Ataluren.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxNenk4MVF0UXptNmFWSWJfSm1HRkdFMkF6S0N5UFpjM2JsaWpHbkc4RExkQmtQaGU5OUtQdjJQMmlWS3djTkl2eG9WTkVMUlZybXZ2SXlXazAwTlNXZm9lQnlNTGdRNGtVUldRNU5neTZIUU1keUZiUGp5cUxmTmY1WGVVbXlhZmROVmh3SDhKNFE4YzdxUVdRdmRNVXpLRHhBcl90ck9pRDlzTW9TZ1Qxb3VyZXo0Z0JORG0zem43dmNPUFVTU2Q4RGxqZjdTWmtLcFlUNVBLYVdZWGxISTdSMzJiRno4RUhabFZnNGd5c21taG5PZkxCeGlrajhoX1JWUG44eDBydTJ4T04tajVKYUJKVDBjV2hDTWd6aG03eVJvOUNvaWJod2lMRXp5MlFISkxGY3FlM1htaXAxYlQyX29YZlFTS0s2R2plZTJVUnlCNzQ?oc=5","date":"2026-03-27","type":"pipeline","source":"MSN","summary":"ARS Pharma rises after Japan nod for neffy nasal spray for allergy - MSN","headline":"ARS Pharma rises after Japan nod for neffy nasal spray for allergy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQU256X01DS1doRDJ6bWJOdFBjeUZsYWctOUl0c0tMVHNnYXRJQUJ0NnJDYnY4VGxvcWlFSk1TREZpeV8tZGFUazNsV3NZdC1jaUdXeDdzekZvVVNLZmFBSVhNNHphSjctS25HT0VTdkQtR1JSS2E5ZXRqbXQ0UXN4WTk2cEF1M1EwZFN3RG5jRmMyTW1SNnhJOWVOOVIxSXJPaFNvOXlCNHE1Nmx3UUNYU0dER2VIN0ppa0t2dHNHOA?oc=5","date":"2026-03-27","type":"regulatory","source":"Stock Titan","summary":"FDA lets younger children use needle-free neffy once they reach 33 lbs. - Stock Titan","headline":"FDA lets younger children use needle-free neffy once they reach 33 lbs.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQcGlWZXJJblI0Yi1HQTRvdHp5WGpINzZSSUVwNkIxN2RKVEVZczV6N1lkNzBrM0NINFg2bWNqVWdOLWxuT3laWlRxV3NKTUZ4d04zU2RnMlhCbm1SclYtdE5jTlA0ZUFUWFFmLWdzaXdaaHZ0cGJkZVd4emxDbHNCMlJZaU9oX2VRMHN1RFRpX3dQaHVyZGxFRFlhWDRlb1RFLTl4S1RJSlFRSkNrOUxQWUw4eDhfUFp6N2RiMw?oc=5","date":"2026-03-11","type":"pipeline","source":"Seeking Alpha","summary":"ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY) - Seeking Alpha","headline":"ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQWHFaOGhzWGpHNUZuUUotYXZzSEoxRUNobko5ZlIwUFdNeEJDLVpWZ294emV6OVRiTlBIcktQUWNpT3hWOEhuRTg0Z3VvXzFWNzQ0d0RUTGUtY2tKYlZFSEZkZDhYRzNvYzFWSkhkMkVteEhkNzNoTTkxS2ZlRU9rUVhKemJWdnRGNUZYenMtV2RwQQ?oc=5","date":"2026-03-09","type":"earnings","source":"Yahoo Finance","summary":"ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization - Yahoo Finance","headline":"ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQTkIwSFJ2S1JqTGdPZmoxaFNZbEJINmt5WEpYY1JXMnF0cHh2MkNLS0N6WGxjUDBqX0szQ2oxeWtJUktFR0lZTUhyRkIxRmRUdXpWWkdNOWg4amh5UzVzcFBsVEg0WjFkSjNId0dUbjl2cnc5V3hEZFBEVDItNlhkMFcta3l1dF9Eb09JZ3pDSWRKclAzNDl2cndmZnJWY2dQSDN4NFZwNmYzSTlkM2dfdUpR?oc=5","date":"2026-03-09","type":"pipeline","source":"Stock Titan","summary":"ARS Pharmaceuticals (Nasdaq: SPRY) grows neffy sales to $72M but posts $171M 2025 loss - Stock Titan","headline":"ARS Pharmaceuticals (Nasdaq: SPRY) grows neffy sales to $72M but posts $171M 2025 loss","sentiment":"neutral"},{"date":"2026-03-09","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPeEJMb3ZBc1dramp1NVBDRE9wNlZ3LVdhUERGNkx0R09Ja3BFcmJDZW1pWG0tWml2Tko1LW5ZdjlOU2h1RmJ6cERrLUNHeFYxeUxtNzNJdDRoRXJnczhSdGVPRWNab0lEUFRQbWtlb29YRkNIMzNyVjdqZEc1ZjdrYXgwcTRfUmpfdjZyM3pTSzVlMEduSEJkRW9rWkoyOTF2ZXEtcldOXzFqNDBWTy1yeVZOZUwxamI3N0tGNA?oc=5","date":"2026-02-23","type":"pipeline","source":"Stock Titan","summary":"Upcoming ARS Pharma call on 2025 results plus March investor conferences - Stock Titan","headline":"Upcoming ARS Pharma call on 2025 results plus March investor conferences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOc0hDT3lyZ2ZLcTczUEFNX09qMmxrU2xlWDBkS3A3THp4TkluSkRlbkEwN3BCMUhScVdNUkhSTWdPYUlNUXFUcTIxRFg5ZHUtOTVPaG1ZY0toWnpuWnlsQVJoc0NWT1ZyeWx4YUQ1STB5cXJzamVOMmR4cWFjTk05WXFiUTl0STlvTUU5V3Rxei1KbjgtaVl6YmszWEZlcG1aYjUxRS1KRFVhaWNfR3BOSk92X0dSYkJBNDdr?oc=5","date":"2026-02-10","type":"pipeline","source":"Stock Titan","summary":"Needle-free epinephrine nasal spray may cut costs and boost patient preference - Stock Titan","headline":"Needle-free epinephrine nasal spray may cut costs and boost patient preference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQRHRfRkgxdS1RWG9vWU90NVV4NTZLX3VfYk00MUFqUXFHSmVQNUcwWlVQeW90NWYtNURCMG00Y3o4cjVTa25HeDAzU0pLQk82YnZvdjAtWXplSHpIWHkweG1iRlFwSGE5U2ltUUpacXota180WlRNcFhDQlAzeWFOcVBqUlZQbjladEJUYXZSU0s?oc=5","date":"2026-02-02","type":"pipeline","source":"Yahoo Finance","summary":"How Investors May Respond To ARS Pharmaceuticals (SPRY) Expanding EURneffy Pediatric Use Across Europe - Yahoo Finance","headline":"How Investors May Respond To ARS Pharmaceuticals (SPRY) Expanding EURneffy Pediatric Use Across Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPVEs5a0ZLd18tUzJQU3RTeFdHRHlLdXU0ZENuZVV1eU95LXRYdFVuY0hHSndodHB0NWgzT2xGWkFmMnZZendoZDlCQ1hLNzlxMHhwaDdBUG0yZGxDMlhzd3BkZDBDdDJuZEpQVVZtMEJ0Z1hwVUI0ME5JY0d4T04xaDdpQ3NnVGtJVzRZYTh4V0sxMm1halVEN3JjZFVfOWJwdXYwVXc1b1BEWlJINEh0OFM5UQ?oc=5","date":"2026-01-29","type":"regulatory","source":"Fierce Pharma","summary":"ARS Pharma TV ad for epinephrine nasal spray Neffy needled by FDA in untitled letter - Fierce Pharma","headline":"ARS Pharma TV ad for epinephrine nasal spray Neffy needled by FDA in untitled letter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPS1VlVXNpbmhsbFA2TTNvTHBBbEZwbmdFN1U3b3hHeGlHVEt5S3o3U05QUXRmWlVjVVZkVFRxbHdnVG9TdjlZMFRtNnNRVF9FV3NkOUt0bmxLVWhBX19fU3MtNm1NaHV3YjlzbGNtUnNrUW81dDZkY1FLa1hONTNrRHdNZzFDSl9GdDhsMHdibFRUc2pEQWZtcGc2Y0tYcDhsWVl1bURfelE4Mm9OYUNRdXItSTVfcFVKVFQ4?oc=5","date":"2026-01-21","type":"pipeline","source":"Stock Titan","summary":"California K-12 schools get free needle-free epinephrine nasal spray - Stock Titan","headline":"California K-12 schools get free needle-free epinephrine nasal spray","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5ubV9TclZaQ2JWOHVPMjZvdGM0T2JuRmsyRG5tRDRJRWVnTDFnOFlfZkVDb2VzM3IydjJyc0xfb19Nc0lEbXNzakpsMHduaGl1eUpfdDhpN2ZiaGNFQ1ZZVUJLTlFpbjluUnhYeVJGQk1nZmZYV2tocmZ0MFRXQQ?oc=5","date":"2026-01-09","type":"regulatory","source":"Yahoo Finance","summary":"ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating - Yahoo Finance","headline":"ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQQTJucFVSWllZVXlmRWFrUE15MjVWXzFlQjN6bnM2dy02bmFoenJVQXZLYmlpemRIbGlBSFJRYU5NOEVqaWYzZlVUT0NrUm94NV83NHVydFF0bERLeFRfeTRXUlFHLWlVWWp1YUlJeVVCcGRyTk9tVkJnOC1ZenZ4WUM4N1FwWjhhYVI3SXNvaUt4QXdnREw5R3Q0T0thTFFmVlRIY3Z1blR6WnI3ZFhudWx0Tk1ONDAxRXJhTA?oc=5","date":"2025-11-10","type":"earnings","source":"Seeking Alpha","summary":"ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating (SPRY) - Seeking Alpha","headline":"ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating (SPRY)","sentiment":"neutral"}],"patents":[{"drugName":"Ataluren","drugSlug":"ataluren","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":4,"phaseCounts":{"marketed":1,"phase_2":1,"phase_1":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Vertex Pharmaceuticals","Cystic Fibrosis Foundation","Gilead Sciences"],"therapeuticFocus":["Cystic Fibrosis","Allergy"],"financials":{"source":"sec_edgar+yahoo","revenue":84278000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":84278000,"period":"2025-12-31"},{"value":89149000,"period":"2024-12-31"},{"value":89149000,"period":"2024-12-31"},{"value":30000,"period":"2023-12-31"},{"value":30000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":13181000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-171298000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":327652000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":158,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":8.09,"previousClose":8.15,"fiftyTwoWeekHigh":18.9,"fiftyTwoWeekLow":6.66,"fiftyTwoWeekRange":"6.66 - 18.9","fiftyDayAverage":9.06,"twoHundredDayAverage":11.43,"beta":0.93,"enterpriseValue":732801024,"forwardPE":-11.3,"priceToBook":7.02,"priceToSales":9.53,"enterpriseToRevenue":8.7,"enterpriseToEbitda":-4.12,"pegRatio":0,"ebitda":-178080992,"ebitdaMargin":-211.3,"freeCashflow":-94588376,"operatingCashflow":-170866000,"totalDebt":168514000,"debtToEquity":147.5,"currentRatio":7.28,"returnOnAssets":-33,"returnOnEquity":-92.3,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":6,"targetMeanPrice":27,"targetHighPrice":34,"targetLowPrice":12,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":16.7,"institutionHeldPercent":93.6,"sharesOutstanding":99297307,"floatShares":41035605,"sharesShort":23719421,"shortRatio":21.17,"shortPercentOfFloat":23.9,"epsTrailing":-1.74,"epsForward":-0.71,"revenuePerShare":0.85,"bookValue":1.15,"officers":[{"age":59,"name":"Mr. Richard E. Lowenthal M.B.A., M.S., MSMSEL","title":"Co-Founder, President, CEO & Director"},{"age":56,"name":"Dr. Sarina  Tanimoto M.B.A., M.D.","title":"Co-Founder & Chief Medical Officer"},{"age":56,"name":"Mr. Brian T. Dorsey M.S.","title":"Chief Operating Officer"},{"age":null,"name":"Dr. Robert  Bell Ph.D.","title":"Co-Founder & Chief Science Officer"},{"age":null,"name":"Ms. Kathleen D. Scott CPA","title":"Chief Financial Officer"},{"age":58,"name":"Mr. Alexander A. Fitzpatrick Esq.","title":"Chief Legal Officer & Secretary"},{"age":null,"name":"Mr. Daniel  Relovsky","title":"Senior Vice President of Marketing"},{"age":null,"name":"Ms. Lynda  Harris","title":"Vice President of Human Resources"}],"industry":"Biotechnology","irWebsite":"","website":"https://ars-pharma.com","phone":"858 771 9307"}}